A new generation of weight-loss drugs has proven remarkably effective, hugely popular, and massively lucrative in the last few years ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

A new obesity drug combining four hormones may outperform Wegovy and Mounjaro. Learn what it means for health, science, and investors.

Volume 17, Issue 5, on May 1, 2025, titled "Oxytocin modulates insulin and GLP-1 secretion in pancreatic islets." ...

The global surge in diabetes cases is a key factor propelling the artificial pancreas device market, as a larger patient base fuels the need for effe ...

Among a plethora of weight-management plans and dietary charts (namely, keto, dash, sirtfood, paleo or crash diet), climbing ...

GLP-1 inhibits glucagon release, which is a hormone that raises blood sugar levels. GLP-1 prolongs gastric emptying and leads ...

Although the detailed mechanism for the stimulation of intra-islet GLP-1 secretion remains to be elucidated and further studies are required, as far ...

A new study led by Ananda Basu, M.D., used novel non-radioactive, stable glucagon tracers for the first time to characterize ...

A study explored glucagon metabolism in humans with and without Type 1 diabetes using stable glucagon tracers. Findings ...

Semaglutide, a synthetic analog of glucagon-like peptide-1 (GLP-1), has garnered attention for its intriguing properties and potential implications in various r ...

The hormone glucagon-like peptide 1 (GLP-1) is released to help stimulate the production of insulin and the uptake of glucose in muscle and other tissues. With the cells now loaded with fuel ...